Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Posted: August 14, 2024 at 2:37 am

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –

Read the original:
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Related Posts